Update information

Minor changes since publication

February 2014: Implementation section updated to clarify human growth hormone (somatropin) is recommended as an option for treating growth failure in children.

July 2010: A minor correction was made to section 6.1 of the guidance. This does not affect the funding direction, which applies from the original date of publication in May 2010.

ISBN: 978-1-4731-5626-5